Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
East Asian patients are known to have differing risks of thrombophilia and bleeding compared with white patients, but few have been included in phase III trials of P2Y12inhibitors. Therefore, the World Heart Federation has produced this evidence-based review and expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients with acute coronary syndrome or undergoing percutaneous coronary intervention.
